210 related articles for article (PubMed ID: 15047912)
21. Potent antitumor activity of IL-13 cytotoxin in human pancreatic tumors engineered to express IL-13 receptor alpha2 chain in vivo.
Kawakami K; Kawakami M; Husain SR; Puri RK
Gene Ther; 2003 Jul; 10(13):1116-28. PubMed ID: 12808442
[TBL] [Abstract][Full Text] [Related]
22. Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice.
Gu JM; Johns A; Morser J; Dole WP; Greaves DR; Deng GG
J Cell Physiol; 2005 Jul; 204(1):73-82. PubMed ID: 15573379
[TBL] [Abstract][Full Text] [Related]
23. Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model.
Stish BJ; Oh S; Vallera DA
J Neurooncol; 2008 Mar; 87(1):51-61. PubMed ID: 18084721
[TBL] [Abstract][Full Text] [Related]
24. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
25. Potent antitumor activity of a urokinase-activated engineered anthrax toxin.
Liu S; Aaronson H; Mitola DJ; Leppla SH; Bugge TH
Proc Natl Acad Sci U S A; 2003 Jan; 100(2):657-62. PubMed ID: 12525700
[TBL] [Abstract][Full Text] [Related]
26. Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells.
Liu TF; Willingham MC; Tatter SB; Cohen KA; Lowe AC; Thorburn A; Frankel AE
Bioconjug Chem; 2003; 14(6):1107-14. PubMed ID: 14624623
[TBL] [Abstract][Full Text] [Related]
27. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC
Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain.
Oh S; Tsai AK; Ohlfest JR; Panoskaltsis-Mortari A; Vallera DA
J Neurosurg; 2011 Jun; 114(6):1662-71. PubMed ID: 21294620
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
Kioi M; Kawakami M; Shimamura T; Husain SR; Puri RK
Cancer; 2006 Sep; 107(6):1407-18. PubMed ID: 16902988
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of proliferation and clonal growth of human breast cancer cells by interleukin 13.
Serve H; Oelmann E; Herweg A; Oberberg D; Serve S; Reufi B; Mücke C; Minty A; Thiel E; Berdel WE
Cancer Res; 1996 Aug; 56(15):3583-8. PubMed ID: 8758930
[TBL] [Abstract][Full Text] [Related]
31. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
Rasch MG; Pass J; Illemann M; Høyer-Hansen G; Lund IK
J Immunol Methods; 2008 Nov; 339(1):55-65. PubMed ID: 18761343
[TBL] [Abstract][Full Text] [Related]
32. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
[TBL] [Abstract][Full Text] [Related]
33. A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.
Tsai AK; Oh S; Chen H; Shu Y; Ohlfest JR; Vallera DA
J Neurooncol; 2011 Jun; 103(2):255-66. PubMed ID: 20830604
[TBL] [Abstract][Full Text] [Related]
34. Binding of interleukin-13 and interleukin-4 to the interleukin (IL)-4/IL-13 receptor of human synovial fibroblasts.
Lutz RA; Feng N; Moser R
J Recept Signal Transduct Res; 1999; 19(1-4):181-90. PubMed ID: 10071757
[TBL] [Abstract][Full Text] [Related]
35. Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor.
Kamiyama H; Zhou G; Roizman B
Gene Ther; 2006 Apr; 13(7):621-9. PubMed ID: 16292350
[TBL] [Abstract][Full Text] [Related]
36. A bispecific recombinant cytotoxin (DTEGF13) targeting human interleukin-13 and epidermal growth factor receptors in a mouse xenograft model of prostate cancer.
Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
Clin Cancer Res; 2007 Nov; 13(21):6486-93. PubMed ID: 17975161
[TBL] [Abstract][Full Text] [Related]
37. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
[TBL] [Abstract][Full Text] [Related]
38. Targeting a methioninase-containing fusion protein to breast cancer urokinase receptors inhibits growth and migration.
Zang XP; Palwai NR; Lerner MR; Brackett DJ; Pento JT; Harrison RG
Anticancer Res; 2006; 26(3A):1745-51. PubMed ID: 16827102
[TBL] [Abstract][Full Text] [Related]
39. Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice.
Li C; Hall WA; Jin N; Todhunter DA; Panoskaltsis-Mortari A; Vallera DA
Protein Eng; 2002 May; 15(5):419-27. PubMed ID: 12034862
[TBL] [Abstract][Full Text] [Related]
40. Intracranial therapy of glioblastoma with the fusion protein DTAT in immunodeficient mice.
Rustamzadeh E; Hall WA; Todhunter DA; Vallera VD; Low WC; Liu H; Panoskaltsis-Mortari A; Vallera DA
Int J Cancer; 2007 Jan; 120(2):411-9. PubMed ID: 17075792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]